Edition:
United States

La Jolla Pharmaceutical Co (LJPC.OQ)

LJPC.OQ on NASDAQ Stock Exchange Capital Market

8.25USD
11:29am EDT
Change (% chg)

$-0.24 (-2.83%)
Prev Close
$8.49
Open
$8.57
Day's High
$8.66
Day's Low
$8.25
Volume
35,059
Avg. Vol
286,286
52-wk High
$38.39
52-wk Low
$5.01

Latest Key Developments (Source: Significant Developments)

Rtw Investments, Lp Reports 8.39% Passive Stake In La Jolla Pharmaceutical Co
Friday, 14 Jun 2019 09:30am EDT 

June 14 (Reuters) - La Jolla Pharmaceutical Co ::RTW INVESTMENTS, LP REPORTS 8.39% PASSIVE STAKE IN LA JOLLA PHARMACEUTICAL CO AS OF JUNE 6 - SEC FILING.  Full Article

La Jolla Pharmaceutical Co Reports Quarterly Loss Per Share $1.17
Monday, 6 May 2019 04:11pm EDT 

May 6 (Reuters) - La Jolla Pharmaceutical Co ::MPANY ANNOUNCES FINANCIAL RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2019 AND HIGHLIGHTS RECENT CORPORATE PROGRESS.QUARTERLY LOSS PER SHARE $1.17.SEES FY 2019 SALES $24 MILLION TO $28 MILLION.LA JOLLA CONTINUES TO EXPECT FULL-YEAR 2019 NET SALES OF $24 MILLION TO $28 MILLION..LA JOLLA PHARMACEUTICAL- FOR THREE MONTHS ENDED MARCH 31, 2019, GIAPREZA NET PRODUCT SALES WERE $4.4 MILLION, COMPARED TO $0.8 MILLION FOR SAME PERIOD IN 2018.AS OF MARCH 31, 2019, LA JOLLA HAD $140.0 MILLION IN CASH AND CASH EQUIVALENTS.LA JOLLA CONTINUES TO EXPECT THAT ITS NET CASH USED IN OPERATING ACTIVITIES IN 2019 WILL BE $89 MILLION TO $94 MILLION..LA JOLLA HAD NO DEBT AS OF MARCH 31, 2019 AND DECEMBER 31, 2018..FY2019 REVENUE VIEW $25.6 MILLION -- REFINITIV IBES DATA.  Full Article

La Jolla Pharmaceutical Company Announces Financial Results For The Three And Twelve Months Ended December 31, 2018
Monday, 4 Mar 2019 04:01pm EST 

March 4 (Reuters) - La Jolla Pharmaceutical Co ::MPANY ANNOUNCES FINANCIAL RESULTS FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2018 AND HIGHLIGHTS RECENT CORPORATE PROGRESS AND KEY OBJECTIVES.SEES FY 2019 SALES $24 MILLION TO $28 MILLION.Q4 SALES $4.2 MILLION VERSUS REFINITIV IBES ESTIMATE OF $4.2 MILLION.LA JOLLA PHARMACEUTICAL - IN 2019, EXPECTS NET CASH USED IN OPERATING ACTIVITIES WILL BE $89 MILLION TO $94 MILLION.AS OF DECEMBER 31, 2018, HAD $172.6 MILLION IN CASH & CASH EQUIVALENTS.QTRLY LOSS PER SHARE $1.73.HAD NO DEBT AS OF DECEMBER 31, 2018.  Full Article

La Jolla Pharma Co Announces Financial Results For The Three And Nine Months Ended September 30, 2018
Wednesday, 24 Oct 2018 04:01pm EDT 

Oct 24 (Reuters) - La Jolla Pharmaceutical Co ::LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES FINANCIAL RESULTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2018.LA JOLLA PHARMACEUTICAL CO - QTRLY NET LOSS PER SHARE, BASIC AND DILUTED $1.93.LA JOLLA PHARMACEUTICAL CO - AS OF SEPTEMBER 30, 2018, LA JOLLA HAD $204.3 MILLION IN CASH AND CASH EQUIVALENTS.  Full Article

La Jolla Pharmaceutical Company Reports Qtrly Loss Per Share Of $2.02
Wednesday, 8 Aug 2018 04:01pm EDT 

Aug 8 (Reuters) - La Jolla Pharmaceutical Co ::MPANY ANNOUNCES FINANCIAL RESULTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2018 AND RECENT CORPORATE PROGRESS.QUARTERLY LOSS PER SHARE $2.02.QUARTERLY TOTAL REVENUE $1.6 MILLION VERSUS NIL REVENUE.  Full Article

Broadfin Capital Reports 5 Percent Passive Stake In La Jolla Pharmaceutical - SEC Filing‍​
Thursday, 11 Jan 2018 05:12pm EST 

Jan 11 (Reuters) - La Jolla Pharmaceutical Co ::BROADFIN CAPITAL LLC REPORTS 5 PERCENT PASSIVE STAKE IN LA JOLLA PHARMACEUTICAL CO AS OF JAN 9 - SEC FILING‍​.  Full Article

La Jolla Pharmaceutical Says Cash Resources Are Expected To Fund Co Into Second Half Of 2018
Friday, 29 Dec 2017 04:40pm EST 

Dec 29 (Reuters) - La Jolla Pharmaceutical Co ::LA JOLLA PHARMACEUTICAL SAYS CASH RESOURCES ARE EXPECTED TO FUND CO INTO SECOND HALF OF 2018 - SEC FILING.  Full Article

La Jolla Says FDA Approved Drug To Treat Critically Low Blood Pressure
Thursday, 21 Dec 2017 06:17pm EST 

Dec 21 (Reuters) - La Jolla Pharmaceutical Co ::U.S. FOOD AND DRUG ADMINISTRATION SAYS APPROVED GIAPREZA (ANGIOTENSIN II) TO TREAT DANGEROUSLY LOW BLOOD PRESSURE.U.S. FDA SAYS GRANTED THE APPROVAL OF GIAPREZA TO LA JOLLA PHARMACEUTICAL COMPANY.U.S. FDA - APPROVES GIAPREZA (ANGIOTENSIN II) INJECTION FOR INTRAVENOUS INFUSION TO INCREASE BLOOD PRESSURE IN ADULTS WITH SEPTIC/OTHER DISTRIBUTIVE SHOCK.  Full Article

La Jolla Pharmaceutical Initiates Multicenter, Randomized, Phase 2 Clinical Study Of LJPC‑401
Monday, 18 Dec 2017 09:00am EST 

Dec 18 (Reuters) - La Jolla Pharmaceutical Co ::INITIATION OF MULTICENTER, RANDOMIZED, PHASE 2 CLINICAL STUDY OF LJPC‑401 IN PATIENTS WITH HEREDITARY HEMOCHROMATOSIS.  Full Article

La Jolla Pharma files for mixed shelf of up to $150 mln ‍​
Friday, 27 Oct 2017 05:42pm EDT 

Oct 27 (Reuters) - La Jolla Pharmaceutical Co :Files for mixed shelf of up to $150 million - SEC filing‍​.  Full Article